Display options
Cite
Bhattacharyya S, Dunlop BW, Mahmoudiandehkordi S, et al. Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. Front Neurosci. 2019;13:926doi: 10.3389/fnins.2019.00926.
Bhattacharyya, S., Dunlop, B. W., Mahmoudiandehkordi, S., Ahmed, A. T., Louie, G., Frye, M. A., Weinshilboum, R. M., Krishnan, R. R., Rush, A. J., Mayberg, H. S., Craighead, W. E., & Kaddurah-Daouk, R. (2019). Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. Frontiers in neuroscience, 13926. https://doi.org/10.3389/fnins.2019.00926
Bhattacharyya, Sudeepa, et al. "Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment." Frontiers in neuroscience vol. 13 (2019): 926. doi: https://doi.org/10.3389/fnins.2019.00926
Bhattacharyya S, Dunlop BW, Mahmoudiandehkordi S, Ahmed AT, Louie G, Frye MA, Weinshilboum RM, Krishnan RR, Rush AJ, Mayberg HS, Craighead WE, Kaddurah-Daouk R. Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. Front Neurosci. 2019 Sep 12;13:926. doi: 10.3389/fnins.2019.00926. eCollection 2019. PMID: 31572108; PMCID: PMC6751322.
Copy Download .nbib Format: NLM
Share it on

Front Neurosci. 2019 Sep 12;13:926. doi: 10.3389/fnins.2019.00926. eCollection 2019.

Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment.

Frontiers in neuroscience

Sudeepa Bhattacharyya, Boadie W Dunlop, Siamak Mahmoudiandehkordi, Ahmed T Ahmed, Gregory Louie, Mark A Frye, Richard M Weinshilboum, Ranga R Krishnan, A John Rush, Helen S Mayberg, W Edward Craighead, Rima Kaddurah-Daouk

Affiliations

  1. Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
  2. Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, United States.
  3. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, United States.
  4. Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States.
  5. Department of Medicine, Duke University, Durham, NC, United States.
  6. Duke Institute for Brain Sciences, Duke University, Durham, NC, United States.
  7. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States.
  8. Department of Psychiatry, Rush University Medical Center, Chicago, IL, United States.
  9. Department of Psychiatry, Texas Tech University, Health Sciences Center, Permian Basin, TX, United States.
  10. Duke-NUS Medical School, Singapore, Singapore.
  11. Center for Advanced Circuit Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

PMID: 31572108 PMCID: PMC6751322 DOI: 10.3389/fnins.2019.00926

Abstract

Major depressive disorder (MDD) is a common and disabling syndrome with multiple etiologies that is defined by clinically elicited signs and symptoms. In hopes of developing a list of candidate biological measures that reflect and relate closely to the severity of depressive symptoms, so-called "state-dependent" biomarkers of depression, this pilot study explored the biochemical underpinnings of treatment response to cognitive behavior therapy (CBT) in medication-free MDD outpatients. Plasma samples were collected at baseline and week 12 from a subset of MDD patients (

Copyright © 2019 Bhattacharyya, Dunlop, Mahmoudiandehkordi, Ahmed, Louie, Frye, Weinshilboum, Krishnan, Rush, Mayberg, Craighead and Kaddurah-Daouk.

Keywords: acylcarnitines; branched-chain amino acids; cognitive behavioral therapy; lipids; major depression; metabolomics

References

  1. Trials. 2012 Jul 09;13:106 - PubMed
  2. Arch Gen Psychiatry. 1998 Feb;55(2):138-44 - PubMed
  3. Eur Psychiatry. 2017 Jun;43:44-50 - PubMed
  4. Diabetes. 2013 Jan;62(1):1-8 - PubMed
  5. Am J Med Genet B Neuropsychiatr Genet. 2019 Mar;180(2):122-137 - PubMed
  6. Mayo Clin Proc. 1997 May;72(5):453-60 - PubMed
  7. Eur Arch Psychiatry Clin Neurosci. 1997;247(3):154-61 - PubMed
  8. PLoS One. 2013 Jul 17;8(7):e68283 - PubMed
  9. Pharmacogenet Genomics. 2012 Apr;22(4):247-53 - PubMed
  10. Neuroreport. 2001 Dec 21;12(18):3939-42 - PubMed
  11. Br J Soc Clin Psychol. 1967 Dec;6(4):278-96 - PubMed
  12. Transl Psychiatry. 2011;1:null - PubMed
  13. PLoS One. 2016 Aug 04;11(8):e0160542 - PubMed
  14. Am J Psychiatry. 2017 Jun 1;174(6):533-545 - PubMed
  15. Transl Psychiatry. 2013 Jan 22;3:e223 - PubMed
  16. Transl Psychiatry. 2018 Jul 10;8(1):130 - PubMed
  17. J Pharm Biomed Anal. 2014 Feb;89:122-9 - PubMed
  18. Stat Med. 1990 Jul;9(7):811-8 - PubMed
  19. Mol Psychiatry. 2019 Jun;24(6):795-807 - PubMed
  20. Am J Psychiatry. 2017 Jun 1;174(6):546-556 - PubMed
  21. Psychiatry Res. 1992 Nov;44(2):85-91 - PubMed
  22. Neuropsychiatr Dis Treat. 2018 Jun 06;14:1451-1461 - PubMed
  23. Psychopharmacology (Berl). 2018 Oct;235(10):3017-3030 - PubMed
  24. Eur Neuropsychopharmacol. 2017 Jun;27(6):554-559 - PubMed
  25. Adv Clin Chem. 2018;84:81-99 - PubMed
  26. PLoS One. 2011;6(10):e26683 - PubMed
  27. Psychiatry Res. 1994 Apr;52(1):55-69 - PubMed
  28. Transl Psychiatry. 2019 Jul 4;9(1):173 - PubMed
  29. BMC Bioinformatics. 2008 Dec 29;9:559 - PubMed
  30. Dialogues Clin Neurosci. 2014 Dec;16(4):479-90 - PubMed
  31. Transl Psychiatry. 2016 Sep 20;6(9):e894 - PubMed
  32. Transl Psychiatry. 2019 Jan 16;9(1):11 - PubMed
  33. J Proteome Res. 2015 Jul 2;14(7):2951-62 - PubMed
  34. J Nerv Ment Dis. 2018 Jun;206(6):481-487 - PubMed
  35. PeerJ. 2018 Aug 31;6:e5410 - PubMed

Publication Types